Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

2.

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR.

Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.

3.

Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.

Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR.

Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743.

4.

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR.

Cancer Res. 2009 Jun 1;69(11):4567-72. doi: 10.1158/0008-5472.CAN-09-0371.

5.

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

Chang Q, Chandrashekhar M, Ketela T, Fedyshyn Y, Moffat J, Hedley D.

Cell Cycle. 2016;15(4):593-604. doi: 10.1080/15384101.2016.1138188.

6.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
7.

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.

Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11.

8.

HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.

Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR.

Cancer Biol Ther. 2012 Aug;13(10):946-55. doi: 10.4161/cbt.20952. Epub 2012 Aug 1.

9.

Wee1 kinase as a target for cancer therapy.

Do K, Doroshow JH, Kummar S.

Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26. Review.

10.

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA.

Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840.

11.

WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.

De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, W├╝rdinger T.

Clin Cancer Res. 2011 Jul 1;17(13):4200-7. doi: 10.1158/1078-0432.CCR-10-2537. Epub 2011 May 11.

12.

HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z.

World J Gastroenterol. 2015 Dec 14;21(46):13004-19. doi: 10.3748/wjg.v21.i46.13004.

13.

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.

Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR.

Sci Rep. 2016 Sep 12;6:33323. doi: 10.1038/srep33323.

14.

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.

Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.

15.

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.

Clin Cancer Res. 2014 Oct 1;20(19):5085-96. doi: 10.1158/1078-0432.CCR-14-1038. Epub 2014 Aug 12.

16.

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.

Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.

Neoplasia. 2015 Oct;17(10):757-66. doi: 10.1016/j.neo.2015.09.006.

17.

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR.

PLoS One. 2010 Nov 29;5(11):e15455. doi: 10.1371/journal.pone.0015455.

18.

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.

Clausse V, Goloudina AR, Uyanik B, Kochetkova EY, Richaud S, Fedorova OA, Hammann A, Bardou M, Barlev NA, Garrido C, Demidov ON.

Cell Death Dis. 2016 Apr 14;7:e2195. doi: 10.1038/cddis.2016.96.

19.

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN.

Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.

20.

HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM.

RNA Biol. 2013 Aug;10(8):1312-23. doi: 10.4161/rna.25274. Epub 2013 Jun 13.

Supplemental Content

Support Center